1-Bromo-5-fluoro-5-methyl-hexane | 158862-47-6

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 1-Bromo-5-fluoro-5-methyl-hexane
• 英文别名: 1-bromo-5-fluoro-5-methylhexane
• CAS: 158862-47-6
• 化学式: C₇H₁₄BrF
• 分子量: 197.091
• InChiKey: TYFDUKAJXBJUBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-Bromo-5-fluoro-5-methyl-hexane 、 N-[4-[4-(ethylamino)-1-hydroxybutyl]phenyl]methanesulfonamide 在 碳酸氢钠 作用下， 以 乙腈 为溶剂， 生成 N-(4-(4-(Ethyl(5-fluoro-5-methylhexyl)amino)-1-hydroxybutyl)phenyl)methanesulfonamide
  参考文献：
  名称：

  Antiarrhythmic methanesulfonamides

  摘要：

  甲磺酰胺类化合物结构如式I所示：##STR1##或其药理学上可接受的盐，其中R3为被C3-7环烷基取代的C1-7烷基，或被一至八个氟原子、一至三个羟基、一至三个C1-5酰氧基或一至三个C1-4烷氧基取代的C1-10烷基。这些化合物作为III类抗心律失常药物具有用途，并且对快速代谢稳定。还描述了使用式I化合物及其组合物治疗心律失常的方法。

  公开号：

  US05405997A1
• 作为产物：
  描述：

  5-hydroxy-5-methylhexyl THP ether 在 N-溴代丁二酰亚胺(NBS) 、 D(+)-10-樟脑磺酸 、 三苯基膦 、 4,4'-二氨基二苯乙烯-2,2'-二磺酸 作用下， 以 甲醇 、 二氯甲烷 、 苯 为溶剂， 反应 25.92h， 生成 1-Bromo-5-fluoro-5-methyl-hexane
  参考文献：
  名称：

  Progress toward the Development of a Safe and Effective Agent for Treating Reentrant Cardiac Arrhythmias:  Synthesis and Evaluation of Ibutilide Analogues with Enhanced Metabolic Stability and Diminished Proarrhythmic Potential

  摘要：

  A series of ibutilide analogues with fluorine substituents on the heptyl side chain was prepared and evaluated for class III antiarrhythmic activity, metabolic stability, and proarrhythmic potential. It was found that fluorine substituents stabilized the side chain to metabolic oxidation. Many of the compounds also retained the ability to increase the refractoriness of cardiac tissue at both slow and fast pacing rates. The potential for producing polymorphic ventricular tachycardia in the rabbit model was dependent on the chirality of the benzylic carbon. The S-enantiomers generally had less proarrhythmic activity than the corresponding racemates. One compound from this series (45E, trecetilide fumarate) had excellent antiarrhythmic activity and metabolic stability and was devoid of proarrhythmic activity in the rabbit model. It was chosen for further development.

  DOI：

  10.1021/jm0004289

文献信息

• Antiarrhythmic methanesulfonamides
  申请人：The Upjohn Company

  公开号：US05405997A1

  公开（公告）日：1995-04-11

  Methanesulfonamides are structurally depicted by Formula I' ##STR1## or its pharmacologically acceptable salts where R.sub.3 is a C.sub.1-7 alkyl substituted with C.sub.3-7 cycloalkyl, or a C.sub.1-10 alkyl substituted with one to eight fluorine atoms, one to three hydroxy, one to three C.sub.1-5 acyloxy or one to three C.sub.1-4 alkoxy substituents. These compounds are useful as Class III antiarrhythmic agents and are stable against rapid metabolism. Methods for treating cardiac arrhythmias with the compounds of Formula I' as well as compositions thereof are also described.

  甲磺酰胺类化合物结构如式I所示：##STR1##或其药理学上可接受的盐，其中R3为被C3-7环烷基取代的C1-7烷基，或被一至八个氟原子、一至三个羟基、一至三个C1-5酰氧基或一至三个C1-4烷氧基取代的C1-10烷基。这些化合物作为III类抗心律失常药物具有用途，并且对快速代谢稳定。还描述了使用式I化合物及其组合物治疗心律失常的方法。
• Vitamin D analogues having a halogen-or azido- substituted side chain
  申请人：Leo Pharmaceutical Products Ltd. A/S (L.o slashed.vens Kemiske Fabrik

  公开号：US05612325A1

  公开（公告）日：1997-03-18

  A compound of formula I ##STR1## wherein R stands for a straight or branched, saturated or unsaturated alkyl group containing from 4 to 12 carbon atoms optionally substituted with a hydroxy group, and possibly containing a ring structure, and in which at least one of the carbon atoms not bearing hydroxyl group is substituted with one or more halogen atoms or an azido group; and prodrugs of I in which one or more of the hydroxy groups are masked as groups which can be reconverted to hydroxy groups in vivo, in pure form or in mixtures. The compounds show antiinflammatory and immunomodulating effects as well as strong activity in inducing differentiation and inhibiting undesirable proliferation of certain cells. The compounds are prepared by oxidizing 1(S),3(R)-bis-(tert-butyldimethylsilyloxy)-20(S)formyl-9,10-seco-pregna-5( E),7(E),10(19)-triene, reducing the resulting product; alkylating the reduction product and then subjecting the alkylated product to triplet-sensitized photoisomerization.

  一种具有公式I的化合物，其中R代表一个直链或支链、饱和或不饱和的烷基基团，含有4至12个碳原子，可选地取代为一个羟基基团，并且可能含有一个环结构，在其中至少有一个不带羟基基团的碳原子被一个或多个卤原子或偶氮基取代；以及I的前体药物，其中一个或多个羟基被掩蔽为在体内可以重新转化为羟基的基团，可以是纯形式或混合物。这些化合物表现出抗炎和免疫调节作用，以及在诱导细胞分化和抑制某些细胞不良增殖方面的强活性。这些化合物是通过氧化1(S),3(R)-双-(叔丁基二甲基硅氧基)-20(S)甲酰-9,10-去甲孕烷-5(E),7(E),10(19)-三烯，还原所得产物；烷基化还原产物，然后将烷基化产物暴露于三重态敏化光异构化来制备的。
• Substituted xanthine derivatives
  申请人：Tung Roger D.

  公开号：US20090239886A1

  公开（公告）日：2009-09-24

  This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

  本发明涉及新型化合物，即取代黄嘌呤衍生物及其药学上可接受的盐。例如，本发明涉及新型取代黄嘌呤衍生物，它们是戊酰异丙基黄嘌呤的衍生物。本发明还提供了包含本发明中的一种或多种化合物和载体的组合物，以及把所述化合物和组合物用于治疗戊酰异丙基黄嘌呤和相关化合物有益的疾病和病况的方法。
• [EN] SUBSTITUTED XANTHINE DERIVATIVES<br/>[FR] DÉRIVÉS DE XANTHINE SUBSTITUÉS
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2011028835A1

  公开（公告）日：2011-03-10

  This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

  本发明涉及新型化合物，它们是取代黄嘌呤衍生物及其药学上可接受的盐。例如，本发明涉及新型取代黄嘌呤衍生物，它们是戊申酰丙胺的衍生物。本发明还提供了包含本发明化合物之一或多个和载体的组合物以及使用所披露的化合物和组合物治疗戊申酰丙胺和相关化合物有益的疾病和病状的方法。
• SUBSTITUTED XANTHINE DERIVATIVES
  申请人：Tung Roger D.

  公开号：US20110053961A1

  公开（公告）日：2011-03-03

  This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

  本发明涉及一种新型化合物，它们是取代黄嘌呤衍生物及其药学上可接受的盐。例如，本发明涉及一种新型的取代黄嘌呤衍生物，它们是戊酰苄氨基甲基黄嘌呤的衍生物。本发明还提供了包括本发明中的一个或多个化合物和载体的组合物，并且揭示了这些化合物和组合物在治疗戊酰苄氨基甲基黄嘌呤和相关化合物有益的疾病和病症的方法中的应用。